Resmed (NYSE: RMD) announced today that it received FDA clearance for its Smart Comfort personalized therapy comfort settings ...
Resmed has received clearance from the U.S. Food and Drug Administration (FDA) for an artificial intelligence (AI)-enabled ...
Jan 16 (Reuters) - ResMed (RMD.N), opens new tab said its respiratory masks containing magnets will remain on the market even though the U.S. Food and Drug Administration classified a recall of the ...
We maintain our USD 258 fair value estimate for narrow-moat ResMed RMD, or AUD 40 per CDI at current exchange rates, following first-quarter fiscal 2024 results. Underlying EBIT of USD 319 million ...
Resmed believes its artificial intelligence-powered approach to personalizing the settings of its connected CPAP machines can lead to better sleep for people with obstructive apnea. | Resmed believes ...
Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.
Please provide your email address to receive an email when new articles are posted on . ResMed CPAP masks that contain magnets are being recalled due to possible magnetic interference with medical ...
SAN DIEGO, Dec. 20, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) is conducting a voluntary global field action to update its guides for all masks with magnets to inform users about potential ...
ResMed focuses on developing medical devices to treat sleep apnoea and other respiratory problems, and on educating caregivers about therapy options. The firm's product portfolio consists of airflow ...
Zacks Investment Research on MSN
Should You Continue to Hold RMD Stock in Your Portfolio?
Resmed Inc. RMD continues to see strong demand for its market-leading mask portfolio, including AirFit, AirTouch and other ranges. The company often relies on strategic acquisitions to strengthen its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback